Sensei Biotherapeutics presents preclinical data on SNS-101

Sensei Biotherapeutics will present new preclinical data from SNS-101 at the Seventh Annual CRI-ENCI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held on September 20 – 23, 2023 in Milan, Italy. “We believe these data further support the potential best-in-class PK and safety profile of SNS-101 and its ability to effectively target VISTA, a promising, but difficult-to-drug immune checkpoint,” said Edward van der Horst, Ph.D., Chief Scientific Officer of Sensei Biotherapeutics. “Restricting drug activity to low pH conditions, such as those found in the acidic tumor microenvironment, allowed us to safely dose SNS-101 in our multi-dose NHP study at increasing levels while maintaining linear elimination kinetics and displaying no target-mediated drug disposition or adverse effects. Paired with new mechanistic data showing SNS-101 can shift immunosuppressive macrophages towards an anti-tumor phenotype, we believe SNS-101 could provide a transformative treatment option for patients. We look forward to sharing data from our ongoing clinical trial later this year.” Presentation Highlights: SNS-101 displayed linear elimination kinetics and no target-mediated drug disposition or adverse effects in a multi-dose GLP toxicology study in cynomolgus monkeys evaluating SNS-101 doses of 1, 10 and 100 mg/kg. In MC38 tumor-bearing mice, SNS-101 alone and in combination with an anti-PD-1 antibody shifted the cytokine expression profile of immunosuppressive myeloid cells in the tumor microenvironment to an anti-tumor, M1 phenotype. The expression of anti-tumor cytokines was correlated with a reduction in tumor size.